Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation clinical trial (NCT06956001). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Firmonertinib compare to the chemotherapy options I might receive?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation clinical trial (NCT06956001). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of Firmonertinib versus the chemotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation clinical trial (NCT06956001). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and check-ups if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation clinical trial (NCT06956001). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation clinical trial (NCT06956001). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation clinical trial (NCT06956001). Contact the study team or your healthcare provider for specific answers.

What this study is about